Clinicopathological Study of Breast Cancer: Adenoid 
Cystic Carcinoma of the Breast

Shengbao Liu; Lin Ruan; Dalong Chai; Lei Zhou; Damin Chai*

doi:10.70711/pmr.v2i5.6713

Clinicopathological Study of Breast Cancer: Adenoid Cystic Carcinoma of the Breast

Shengbao Liu, Lin Ruan, Dalong Chai, Lei Zhou, Damin Chai*

Abstract

Objective: To study the clinicopathological features of Adenoid cystic carcinoma of the breast (AdCC). Methods: The clinical
data and follow-up data of 7 AdCC patients admitted to the First Affiliated Hospital of Bengbu Medical University from 2019 to 2023 were
analyzed, and their clinical imaging features, pathological sections, histochemical results and molecular pathological characteristics were analyzed. Results: All the 7 patients were female, with an average age of 62.5 years (30-90 years). Most of the tumors were well-circumscribed
gray-white masses. Mammography showed patchy and nodular hyperdensity shadows with unclear boundaries. Microscopically, the tumor
nests were composed of glandular epithelium, myoepithelial/basal cells in cribriform, trabecular-tubular and solid structures. There were 1
case of grade ?, 3 cases of grade ? and 3 cases of grade ?. CK5/6 and CD117 were expressed in the glandular epithelium and p63, SMA
and CD117 were expressed in the myoepithelium and basal cells. Fluorescence in situ hybridization(FISH) detection of MYB gene rearrangement was positive for MYB gene break. Conclusion: AdCC is a malignant tumor with indolent biological behavior. It can be distinguished
from other breast cancers by combining its imaging features, histomorphology and immunophenotype, so as to make accurate diagnosis and
better clinical guidance.

Keywords

Adenoid cystic carcinoma of the breast; Pathological diagnosis; Imaging characteristics

Full Text:

PDF

Included Database

References

[1] Zhang W, Fang Y, Zhang Z, Wang J. Management of Adenoid Cystic Carcinoma of the Breast: A Single-Institution Study. Front Oncol.

2021. 11: 621012.

[2] Rypel J, Kubacka P, Myka?a-Cie?la J, Paj?k J, Bulska-B?dkowska W, Chudek J. Locally Advanced Adenoid Cystic Carcinoma of the

Breast-A Case Report with a Review of the Literature. Medicina (Kaunas). 2023. 59(11).

[3] Vranic S, Bender R, Palazzo J, Gatalica Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol. 2013. 44(3): 301-9.

[4] Chan JK. The wonderful colors of the hematoxylin-eosin stain in diagnostic surgical pathology. Int J Surg Pathol. 2014. 22(1): 12-32.

[5] Hussaini HM, Seo B, Rich AM. Immunohistochemistry and Immunofluorescence. Methods Mol Biol. 2023. 2588: 439-450.

[6] Kleer CG, Oberman HA. Adenoid cystic carcinoma of the breast: value of histologic grading and proliferative activity. Am J Surg

Pathol. 1998. 22(5): 569-75.

[7] Kepil N, Batur ?, Kain ZE, et al. Role of Immunohistochemistry in the Differential Diagnosis of Pediatric Renal Tumors: Expression of

Cyclin D1, Beta-Catenin, PDGFR-Alpha, and PTEN. Turk Patoloji Derg. 2022. 38(2): 83-89.

[8] Martelotto LG, De Filippo MR, Ng CK, et al. Genomic landscape of adenoid cystic carcinoma of the breast. J Pathol. 2015. 237(2):

179-89.

[9] Fernndez de Los Reyes I, Crdoba Iturriagagoitia A, Chouza Sanin M, Aguiar Losada B, Larrea Ramirez A, Ruz de Aza Ciria Y. [Adenoid cystic carcinoma of the breast, 22 years of experience]. Rev Esp Patol. 2020. 53(4): 206-212.

[10] Thomas DN, Asarian A, Xiao P. Adenoid cystic carcinoma of the breast. J Surg Case Rep. 2019. 2019(1): rjy355.

[11] Li JX, Zhang XM, Xiao YX, Tang ZM, Huang T, Ming J. Male Adenoid Cystic Carcinoma of the Breast. J Med Cases. 2021. 12(12):

503-510.

[12] Cserni G, Quinn CM, Foschini MP, et al. Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. Cancers

(Basel). 2021. 13(22).

[13] Miyai K, Schwartz MR, Divatia MK, et al. Adenoid cystic carcinoma of breast: Recent advances. World J Clin Cases. 2014. 2(12):

732-41.

[14] Law YM, Quek ST, Tan PH, Wong SL. Adenoid cystic carcinoma of the breast. Singapore Med J. 2009. 50(1): e8-11.

[15] Mastropasqua MG, Maiorano E, Pruneri G, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic

carcinoma of the breast. Mod Pathol. 2005. 18(10): 1277-82.

[16] Nakai T, Ichihara S, Kada A, et al. The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may

aid in differentiating it from its mimickers. Virchows Arch. 2016. 469(2): 213-22.

[17] Warm HL, Kandt LD, Schaumann N, et al. Immunohistochemical marker profiles for the differentiation of collagenous spherulosis from

adenoid cystic carcinoma of the breast. Hum Pathol. 2024. 148: 7-13.

[18] Shamir ER, Bean GR, Schwartz CJ, et al. Solid-Basaloid Adenoid Cystic Carcinoma of the Breast: An Aggressive Subtype Enriched for

Notch Pathway and Chromatin Modifier Mutations With MYB Overexpression. Mod Pathol. 2023. 36(12): 100324.

[19] Gou WB, Yang YQ, Song BW, He P. Solid basal adenoid cystic carcinoma of the breast: A case report and literature review. Medicine

(Baltimore). 2024. 103(3): e37010.

[20] Ji J, Zhang F, Duan F, et al. Distinct clinicopathological and genomic features in solid and basaloid adenoid cystic carcinoma of the

breast. Sci Rep. 2022. 12(1): 8504.

[21] Poling JS, Yonescu R, Subhawong AP, et al. MYB Labeling by Immunohistochemistry Is More Sensitive and Specific for Breast Adenoid Cystic Carcinoma than MYB Labeling by FISH. Am J Surg Pathol. 2017. 41(7): 973-979.

[22] Persson M, Andrn Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in

carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009. 106(44): 18740-4.

DOI: http://dx.doi.org/10.70711/pmr.v2i5.6713

Refbacks

There are currently no refbacks.